Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
Open Access
- 1 December 2011
- journal article
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 43 (4), 236-243
- https://doi.org/10.4143/crt.2011.43.4.236
Abstract
The aims of this study are to find out whether the sequence of chemotherapeutic regimens including second- and third-line taxane and irinotecan influences the survival of patients with unresectable gastric carcinoma and to identify clinical characteristics of patients with improved response. Fifty gastric carcinoma patients who were treated by third-line sequential chemotherapy between November 2004 and July 2010 were enrolled in this study. Their overall survival (OS) and time to progression (TTP) were set up as primary and secondary end points. For the sequence of chemotherapy regimen, two arms were used. Arm A was defined as 5-fluorouracil (5-FU)+cisplatin (FP) or folinic acid, 5-FU and oxaliplati (FOLFOX), followed by folinic acid, 5-FU and irinotecan (FOLFIRI), and paclitaxel or docetaxel plus 5-FU, with or without epirubicin. Arm B was defined as FP or FOLFOX, followed by paclitaxel or docetaxel plus 5-FU, and FOLFIRI. The median OS of all patients was 16.0 months (95% confidence interval, 13.6 to 18.3 months), which is longer than historical control of patients who did not receive third-line chemotherapy. The sequence of second and third-line regimen, including irinotecan and taxane, did not present significant difference in OS or TTP after failure of 5-FU with platinum chemotherapy. In survival analysis of patients' clinicopathologic characteristics, poor prognosis was shown in patients with poorly differentiated histologic features, elevated serum carcinoembryonic level, and shorter TTP of first line chemotherapy. It is possible for patients to respond differently to chemotherapy due to differences in clinical features and underlying gene expression profiles. Development of individualized chemotherapy regimens based on gene expression profiles is warranted.Keywords
This publication has 24 references indexed in Scilit:
- Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2008Cancer Research and Treatment, 2011
- A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapyAnnals Of Oncology, 2010
- Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial designCancer Chemotherapy and Pharmacology, 2010
- A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancerBMC Cancer, 2009
- Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancerAnnals of Oncology, 2008
- Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor AnalysisJapanese Journal of Clinical Oncology, 2007
- Retrospective Evaluation of Sequential Outpatient Chemotherapy for Advanced Gastric CancerChemotherapy, 2007
- Evolving Chemotherapy for Advanced Gastric CancerThe Oncologist, 2005
- Review of second-line chemotherapy for advanced gastric adenocarcinomaClinical Oncology, 2005
- Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancerAnnals of Oncology, 1997